Tyra Biosciences, Inc. (TYRA) stock
TYRANasdaqPharmaceutical PreparationsFiscal year ends December 31
$19.57−0.17 (-0.86%)
Close on Nov 17, 2026Market cap $1.17BP/E –Yield –
Tyra Biosciences r&d expenses
Research and development expenses are spending on new products and technology.
Tyra Biosciences's R&D Expenses for the twelve months ending Jun 30, 2026 was $126.32M, up 34.2% year over year. For fiscal 2025 it was $102.93M, up 28.5% from the year before. The highest annual figure on record is $102.93M in fiscal 2025.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $102.93M | +28.5% |
| FY2024 | Dec 31, 2024 | $80.08M | +28.1% |
| FY2023 | Dec 31, 2023 | $62.52M | +45.4% |
| FY2022 | Dec 31, 2022 | $43.01M | +108.4% |
| FY2021 | Dec 31, 2021 | $20.64M | +186.5% |
| FY2020 | Dec 31, 2020 | $7.20M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $39.20M | +61.2% |
| Q1 FY2026 | Mar 31, 2026 | $33.47M | +34.1% |
| Q4 FY2025 | Dec 31, 2025 | $28.19M | +27.1% |
| Q3 FY2025 | Sep 30, 2025 | $25.47M | +12.2% |
| Q2 FY2025 | Jun 30, 2025 | $24.31M | +35.1% |
| Q1 FY2025 | Mar 31, 2025 | $24.96M | +45.1% |
| Q4 FY2024 | Dec 31, 2024 | $22.18M | +7.3% |
| Q3 FY2024 | Sep 30, 2024 | $22.70M | +17.8% |
| Q2 FY2024 | Jun 30, 2024 | $18.00M | +48.0% |
| Q1 FY2024 | Mar 31, 2024 | $17.20M | +65.3% |
| Q4 FY2023 | Dec 31, 2023 | $20.68M | +98.8% |
| Q3 FY2023 | Sep 30, 2023 | $19.27M | +76.6% |
| Q2 FY2023 | Jun 30, 2023 | $12.16M | +1.0% |
| Q1 FY2023 | Mar 31, 2023 | $10.41M | +7.9% |
| Q4 FY2022 | Dec 31, 2022 | $10.40M | +43.4% |
| Q3 FY2022 | Sep 30, 2022 | $10.92M | +99.0% |
| Q2 FY2022 | Jun 30, 2022 | $12.05M | +175.0% |
| Q1 FY2022 | Mar 31, 2022 | $9.65M | +173.9% |
| Q4 FY2021 | Dec 31, 2021 | $7.25M | +147.6% |
| Q3 FY2021 | Sep 30, 2021 | $5.48M | +194.5% |
| Q2 FY2021 | Jun 30, 2021 | $4.38M | – |
| Q1 FY2021 | Mar 31, 2021 | $3.52M | – |
| Q4 FY2020 | Dec 31, 2020 | $2.93M | – |
| Q3 FY2020 | Sep 30, 2020 | $1.86M | – |
See a number that looks wrong?